Court blocks generic Cymbalta until 2013; Medicis gets panel nod for new Restylane use;

@FiercePharma: Top 10 Biopharma CEO salaries of 2010. Report | Follow @FiercePharma

> Eli Lilly said a federal court is blocking low-cost generic versions of Cymbalta from the market until the patents supporting the drug expire in 2013. News

> The popular wrinkle-filler Restylane, made by Medicis Pharmaceutical, should be approved to plump up thin lips, an FDA advisory panel said. Story

> Medco Health Solutions has posted a higher-than-expected quarterly profit as the U.S. pharmacy benefit manager dispensed a greater percentage of more profitable generic drugs. Report

> Novartis has won approval from the European Union for a single-pill treatment for high blood pressure, Rasilamlo, incorporating aliskiren and amlodipine. Item

> Spectrum Pharmaceuticals said it will report that its product sales surged to around $40 million in the first quarter, almost six times its total from a year ago. Article

> Drug wholesaler AmerisourceBergen reported quarterly earnings that topped expectations, helped by higher sales of specialty generics. Item

> Johnson & Johnson's newfound dominance of the orthopedic-device market, cemented by its $21.3 billion acquisition of Synthes, may drive rivals Zimmer and Stryker to seek purchases of their own. Story

> A Swiss appeals court has ruled that a series of television shows about the possible side effects of Bayer birth control pills Yaz and Yasmin were not inaccurate; therefore, legal intervention was not warranted. News

Biotech News

 @FierceBiotech:  Merck takes its case for boceprevir to the FDA panel. News | Follow @FierceBiotech

 @JohnCFierce: Still glowing from yesterday's FDA review of telaprevir, Vertex stock is up another $1.57 so far today, as boceprevir faces a vote. Follow @JohnCFierce

> Pfizer lays out slate of Ph3 successes for its crucial RA program. Article 

> Vertex offers a blockbuster case for telaprevir. News

> Merck wins unanimous FDA panel support for blockbuster boceprevir. Story

Vaccines News

> FDA clears Menactra for infants. Story 

> Merck, Sanofi start Ph3 pediatric vax trial. Item

> Immune Design recruits former Elan exec. News

> Caliber opens new TX manufacturing facility. Report 

> Gates gives $8.9M to fund new malaria vaccine approach. News 

Manufacturing News

> Label-error recalls highlight weak link. News 

> Manufacturing-savvy generic cos. set for business boost. Report

> Finally, track/trace action instead of talk. Story 

> FDA system would speed excipient screening. Article 

> Drug-promo poster collection visits Philadelphia. Report

> Teva begins ramp-up at CA injectables plant. Article 

And Finally... If you've ever lost your keys or stuck the milk in the cupboard and the cereal in the refrigerator, you may have been the victim of a tired brain region that was taking a quick nap. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.